Atossa Therapeutics announces AACR poster presentation on (Z)-endoxifen in McCune-Albright syndrome
ATOS•AACR poster highlights preclinical (Z)-endoxifen data
Atossa Therapeutics released a July 21, 2026 update on preclinical (Z)-endoxifen data in McCune-Albright syndrome presented at an AACR rare cancers meeting.
- The poster outlined a proposed dual mechanism targeting estrogen receptor signaling and PKC-β/AKT pathways to address peripheral precocious puberty linked to the disorder.
- Atossa flagged the findings as supporting further evaluation of (Z)-endoxifen in the indication, with potential relevance to estrogen-driven cancers.
